Table 2.

Rationale for therapy recommendations

Therapeutic agent (trading name) and number of recommendations	Targets	Overview of current FDA approval in different entities	Overview of current EMA approval in different entities
Cetuximab (Erbitux) N = 3	EGFR expression	CRC, HNSCC	CRC, HNSCC
Pembrolizumab (Keytruda) N = 3	PD‐1, hypermutability	Melanoma, NSCLC, HNSCC, HL, urothelial carcinoma, microsatellite instability‐high cancer, gastric cancer, cervical cancer	Melanoma, NSCLC, HNSCC, HL, urothelial carcinoma
Sunitinib (Sutent) N = 2	PDGFR, KIT, VEGFR, RET, FLT3	RCC, PDAC, GIST	RCC, PDAC, GIST
Dasatinib (Sprycel) N = 1	BCR/ABL, Src family, PDGFR	Ph + CML, Ph + ALL	Ph + CML, Ph + ALL
Nintedanib (Vargatef, Ofev) N = 1	PDGFR, FLT3, FGFR, VEGFR	Idiopathic pulmonary fibrosis	NSCLC
Everolimus (Afinitor) N = 1	mTOR expression	Breast cancer, PNET, RCC, renal angiomyolipoma,	Breast cancer, RCC, neuroendocrine tumors of pancreatic, gastrointestinal or lung origin

ABL, Abelson murine leukemia viral oncogene homolog 1; ALL, acute lymphatic leukemia; BCR, breakpoint cluster region; CML, chronic myleloid leukemia; EGFR epidermal growth factor receptor; EMA, European Medicines Agency; FDA, Food and Drug Administration; FLT3, fms like tyrosine kinase 3; GIST, gastrointestinal stromal tumor; HL, Hodgkin’s lymphoma; HNSCC, head and neck squamous cell carcinoma; NSCLC, non‐small cell lung carcinoma; PD‐1, programmed cell death protein 1; PDAC, pancreatic ductal adenocarcinoma; PDGFR, platelet‐derived growth factor receptor; Ph+, Philadelphia chromosome positive; p‐mTOR, phosphorylated mammalian target of rapamycin; RCC, renal cell carcinoma; RET, rearranged during transfection; TP53, tumor protein 53; VEGFR, vascular endothelial growth factor.